TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17585662
Drug: Sequential acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential acupuncture method
Study: 16304265
Drug: Lung volume
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung volume reduction surgery (LVRS) and optimal medical therapy
Study: 16304265
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy only
Study: 9031992
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg daily for 27 nights (preceded by 2 nights of placebo and followed by 3 nights of placebo)
Study: 9031992
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 nights before and 3 nights after zolpidem administration)
Study: 1523530
Drug: Lactobacillus suppository
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus suppository
Study: 31645180
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy (two 30- to 45-minute sessions weekly for 12 weeks)
Study: 31645180
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug treatments and routine daily care (Control)
Study: 26678518
Drug: Higher-dose media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose media buy (3 times standard dose)
Study: 26678518
Drug: Standard-dose media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose media buy
Study: 23920107
Drug: Specific education
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific education program on appropriate indications of intravenous lines
Study: 18693456
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus rosiglitazone (4 mg/d)
Study: 1330127
Drug: Short-term group
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term group therapy
Study: 4073101
Drug: Ticarcillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin (3 g) plus clavulanate potassium (200 mg) administered intravenously
Study: 4073101
Drug: Piperacillin (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (125 to 200 mg/kg per day) administered intravenously
Study: 31024557
Drug: Poly-ICLC (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-ICLC (1.4 mg subcutaneously, two consecutive daily doses)
Study: 18197495
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human growth hormone (rhGH) 0.15 IU/kg daily for 7 days postoperatively
Study: 18197495
Drug: Placebo (menstruum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (menstruum) injection daily for 7 days postoperatively
Study: 15990570
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg daily dose of hydroxyurea
Study: 15990570
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of hydroxyurea (900 mg and 1200 mg)
Study: 12149667
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg/day)
Study: 10541778
Drug: Warfarin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (10 mg on day 1 and 2.5‐10 mg on days 2‐21)
Study: 343489
Drug: Papaverine (5‐‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (5‐‐10 mg per kg body weight)
Study: 30782183
Drug: Single-dose antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antimicrobial prophylaxis (AP) with cotrimoxazole
Study: 24257591
Drug: Daily monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily monitoring of traumatic symptoms and substance use behaviors using PDAs
Study: 24257591
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily monitoring assessments (only pre- and post-monitoring online assessments)
Study: 15451221
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (n=857)
Study: 15451221
Drug: Parenteral penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral penicillin (n=845)
Study: 11394606
Drug: Tibial eminence
Normalized name: Eminence Bright Skin Starter Set Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibial eminence fracture treatment
Study: 8092118
Drug: Group I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I: surgery if possible, otherwise biopsy followed by whole-brain irradiation to a total dose of 34 Gy in 4 fractions, VCR (2 mg i.v.), and BCNU (80 mg/m2 i.v.) every 6 weeks
Study: 8092118
Drug: Group II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II: irradiation as Group I plus VP16 (75 mg/m2) every 3 weeks and BCNU (50 mg/m2 i.v.) every 6 weeks
Study: 8092118
Drug: Group III:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III: 60 Gy in 30 fractions to the tumor bed plus VCR (2 mg i.v.), BCNU (50 mg/m2 i.v.), and CDDP (15 mg/m2 i.v.) every 6 weeks
Study: 2979243
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine cigarettes (1.91 mg)
Study: 2979243
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine cigarettes (0.17 mg)
Study: 22545738
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBASP and nefazodone
Study: 19447020
Drug: Lutein (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (12 mg/day) plus green tea extract (200 mg/day)
Study: 17218777
Drug: 1E10 anti-idiotype
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1E10 anti-idiotype vaccine (2 mg of aluminum hydroxide-precipitated 1E10 MAb, four biweekly injections followed by six doses at 28-day intervals)
Study: 17218777
Drug: 1E10 anti-idiotype
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1E10 anti-idiotype vaccine
Study: 12196750
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel (EE/LNG)
Study: 8722664
Drug: Appropriate medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate medical and surgical therapy
Study: 448786
Drug: Oxamniquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (15 mg/kg single oral dose)
Study: 448786
Drug: Oxamniquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (15 mg b.d. for a single day)
Study: 28219295
Drug: Pharmaceutical schemas
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical schemas (beliefs about medicines)
Study: 26936842
Drug: Ethanol solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol solution
Study: 22954403
Drug: Colistin and
Normalized name: Colistin and hydrocortisone and neomycin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin and rifampicin combination
Study: 19944006
Drug: Sublingual specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual specific immunotherapy (SLIT) for children with allergic rhino-conjunctivitis and seasonal asthma for a duration of no less than three years.
Study: 19944006
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT) for pediatric allergic rhinitis and asthma.
Study: 17762711
Drug: Citalopram (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (7.5 mg)
Study: 14752635
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg oral ALA (low-dose)
Study: 14752635
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg oral ALA (high-dose)
Study: 14752635
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg in two fractions 4 and 6 h before PDT
Study: 10359882
Drug: Methylprednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (40 mg/1.73 m2)
Study: 2712403
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.3 M sodium citrate solution orally 5 min before induction of anaesthesia (group C)
Study: 2712403
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without antacids (group T)
Study: 2560
Drug: Insulin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.2 U/kg b.w.)
Study: 2560
Drug: Bromazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (0.1 mg/kg b.w.)
Study: 2560
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Bromazepam
Study: 27533077
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy delivered via mail
Study: 25779708
Drug: Morphine injection
Normalized name: morphine Injection
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine injection
Study: 25779708
Drug: Morphine-midazolam solution
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Morphine-midazolam solution
Study: 23343906
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) 0.1 mg/kg·day with prednisone at 0.5 mg/kg·day
Study: 23343906
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) 0.5-0.75 g/m(2)·month, i.v. with prednisone at 0.8 mg/kg·day
Study: 21078629
Drug: Transdermal 17β-oestradiol
Normalized name: 17β-oestradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17β-oestradiol (50 µg/day)
Study: 19797249
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.3 ml
Study: 19797249
Drug: Sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.7 ml
Study: 17113886
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg/24 hr
Study: 14760143
Drug: Individualised complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised complete written action plans with 2-4 action points and both inhaled corticosteroids (ICS) and oral corticosteroids (OCS)
Study: 11313314
Drug: Peginterferon alpha2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alpha2a (180 microg once weekly for 48 weeks)
Study: 11313314
Drug: Standard interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interferon alpha2a (thrice weekly for 48 weeks)
Study: 9150824
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy supplementing exposure (EC)
Study: 31290948
Drug: Short-term treatment
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term treatment of internet and computer game addiction (STICA)
Study: 28532623
Drug: Standard sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sequential (SS) treatment: lansoprazole 30mg b.i.d. + amoxicillin 1g b.i.d. for 5 days, followed by lansoprazole 30mg b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d. for 5 days
Study: 28532623
Drug: Extended sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended sequential (ES) treatment: same as SS but for 7+7 days
Study: 28532623
Drug: Extended sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended sequential + bismuth (ES+B) treatment: same as ES but with colloidal bismuth 600mg b.i.d. for 14 days
Study: 25672574
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle
Study: 17209788
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix derivative (EMD) treatment
Study: 17209788
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no EMD treatment)
Study: 15067859
Drug: MF59-adjuvanted hepatitis
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted hepatitis B vaccine
Study: 15067859
Drug: Engerix-B (alum-adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (alum-adjuvanted yeast-derived HBV vaccine)
Study: 9054741
Drug: Integrilin (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrilin (highest dose)
Study: 9728228
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) infusion of 1 mg kg‐1 h‐1 during surgery
Study: 29185133
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise program (twice a week for 12 weeks)
Study: 28901796
Drug: 5-mg saxagliptin
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg saxagliptin
Study: 29350176
Drug: Prototype 4-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype 4-mg nicotine lozenge
Study: 29350176
Drug: Prototype III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype III 4-mg nicotine lozenge
Study: 29350176
Drug: All prototype
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All prototype 4-mg nicotine lozenges
Study: 29350176
Drug: Prototype 4-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype 4-mg nicotine lozenges
Study: 29350176
Drug: Reference 4-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference 4-mg nicotine lozenge
Study: 21978726
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Ferric Carboxymaltose (FCM) in two doses 5 days apart
Study: 21978726
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ferric Carboxymaltose (FCM) given on day 28
Study: 21978726
Drug: Additional 500
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional 500 mg Ferric Carboxymaltose (FCM) for those not responding to initial treatment
Study: 8730253
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg b.d. for 4 weeks plus amoxycillin 1 g t.d.s. during the last 2 weeks
Study: 8730253
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 4 weeks plus classical triple therapy (tripotassium dicitratobismuthate 240 mg b.d., amoxycillin 1 g t.d.s. and tinidazole 500 mg b.d.) for the last 2 weeks
Study: 31409606
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 4 weeks
Study: 29084737
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive antiplatelet therapy (vorapaxar and ticagrelor pooled)
Study: 29084737
Drug: Background antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background antiplatelet therapy (aspirin monotherapy)
Study: 27401475
Drug: WelTel SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WelTel SMS intervention (interactive weekly SMS 'How are you?')
Study: 22648287
Drug: Therapeutic cervical
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cervical facet joint injections at bilateral C5/C6 and C6/C7
Study: 22648287
Drug: Non-injection group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-injection group (group N)
Study: 20543705
Drug: DAILIES AquaComfort
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAILIES AquaComfort Plus for daily disposable, daily wear
Study: 17010102
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg G. biloba + 100 mg cilostazol
Study: 17010102
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg G. biloba + 75 mg clopidogrel
Study: 17010102
Drug: G. biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. biloba
Study: 17010102
Drug: Individual doses
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual doses of cilostazol or clopidogrel
Study: 16216721
Drug: Virgin argan
Normalized name: argan oil
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virgin argan oil (VAO) 25 ml/day
Study: 16216721
Drug: Extra virgin
Normalized name: Jarrow Formulas Extra Virgin Coconut Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra virgin olive oil (EVO) 25 ml/day
Study: 12670060
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day for 28 days, then 10 mg/day thereafter
Study: 7554703
Drug: Physostigmine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (2 to 12 mg/day)
Study: 7554703
Drug: Sustained low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained low-dose steady-state intravenous infusion of physostigmine (0.5 to 25 mg/day)
Study: 7554703
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose physostigmine (1 to 1.5 mg for 45 to 60 minutes)
Study: 7554703
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose physostigmine
Study: 1981022
Drug: Bendrofluazide 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 5 mg each morning plus placebo at night
Study: 30606197
Drug: eHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth intervention (webpage with monthly video clips and baby food recipes)
Study: 26386540
Drug: VGX-3100 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: VGX-3100 (6 mg, intramuscularly at 0, 4, and 12 weeks)
Study: 26386540
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL, intramuscularly at 0, 4, and 12 weeks)
Study: 22155910
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet (GPO-VIR Z30)
Study: 20453709
Drug: Liquid formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulations
Study: 22155910
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GG genotype
Study: 22155910
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GT genotype
Study: 22155910
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 TT genotype
Study: 15657502
Drug: Thallium-201 (201Tl)
Normalized name: thallium
DrugBank: Thallium Tl-201 (DB15361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thallium-201 (201Tl) injection of 111-130 MBq at peak exercise and a second injection of 18.5-37 MBq of 201Tl 15 min before rest images.
Study: 11847938
Drug: brasofensine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: brasofensine 0.5 mg
Study: 11847938
Drug: brasofensine 1
Normalized name: Brasofensine
DrugBank: Brasofensine (DB04857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: brasofensine 1 mg
Study: 11847938
Drug: brasofensine 2
Normalized name: Brasofensine
DrugBank: Brasofensine (DB04857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: brasofensine 2 mg
Study: 11847938
Drug: brasofensine 4
Normalized name: Brasofensine
DrugBank: Brasofensine (DB04857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: brasofensine 4 mg
Study: 7476342
Drug: Acipimox 500
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 500 mg orally, 120 minutes before GHRH injection
Study: 7476342
Drug: Acipimox 500
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 500 mg orally
Study: 2277129
Drug: FS 205-397
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS 205-397 (250 mg)
Study: 2277129
Drug: FS 205-397
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS 205-397 (500 mg)
Study: 380335
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (extended field radiotherapy followed by six cycles of MOPP chemotherapy)
Study: 22986417
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution (0.3 ml kg(‐1) h(‐2) containing potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)
Study: 29427697
Drug: Oral diabetes
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diabetes medications
Study: 18515451
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate 500 mg b.d. for 7 days
Study: 17072963
Drug: Mebendazole (MBZ)
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole (MBZ) 200 mg taken three times per day (TID) for five days